TALPHERA, INC.

Nasdaq:TLPH

Pharmaceutical Preparations·SAN MATEO, CA

Summary Financials

Revenue

$343,000

-98.0% YoY

FY 2019

Adj. EBITDA

-$16.6M

-4833.2% margin

FY 2024

Net Income

-$18.4M

-5363.6% margin

FY 2024

EPS (Diluted)

$5.72

FY 2023

Stock Price

$0.88

-0.4%

2026-03-10

52W Range

$0.38 – $1.57

P/E Ratio

0.2x

Market Cap

$41.2M

Cash

$5.7M

FY 2024

Total Debt

$5.0M

FY 2022

Net Cash

$714,000

FY 2022

Enterprise Value

$40.5M

Debt / EBITDA

0.0x

FY 2019

EV / EBITDA

-2.4x

Employees

—

Revenue

$343,000

-98.0% YoY

FY 2019

Adj. EBITDA

-$16.6M

-4833.2% margin

FY 2024

Net Income

-$18.4M

-5363.6% margin

FY 2024

EPS (Diluted)

$5.72

FY 2023

Stock Price

$0.88

-0.4%

2026-03-10

52W Range

$0.38 – $1.57

P/E Ratio

0.2x

Market Cap

$41.2M

Cash

$5.7M

FY 2024

Total Debt

$5.0M

FY 2022

Net Cash

$714,000

FY 2022

Enterprise Value

$40.5M

Debt / EBITDA

0.0x

FY 2019

EV / EBITDA

-2.4x

Employees

—